Upregulation of minichromosome maintenance complex component 3 during epithelial-to-mesenchymal transition in human prostate cancer

Paul A. Stewart; Zahraa I. Khamis; Haiyen E. Zhau; Peng Duan; Quanlin Li; Leland W.K. Chung; Qing-Xiang Amy Sang

doi:10.18632/oncotarget.16835

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Upregulation of minichromosome maintenance complex component 3 during epithelial-to-mesenchymal transition in human prostate cancer

Paul A. Stewart, Zahraa I. Khamis, Haiyen E. Zhau, Peng Duan, Quanlin Li, Leland W.K. Chung and Qing-Xiang Amy Sang _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:39209-39217. https://doi.org/10.18632/oncotarget.16835

Metrics: PDF 1293 views | HTML 2129 views | ?

Abstract

Paul A. Stewart1,*, Zahraa I. Khamis1,4,*, Haiyen E. Zhau2,*, Peng Duan2, Quanlin Li2, Leland W.K. Chung2 and Qing-Xiang Amy Sang1,3

1Department of Chemistry & Biochemistry, Florida State University, Tallahassee, FL, United States of America

2Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America

3Institute of Molecular Biophysics, Florida State University, Tallahassee, FL, United States of America

4Laboratory of Cancer Biology and Molecular Immunology, Department of Biochemistry, Faculty of Sciences, Lebanese University, Beirut, Lebanon

*These authors have contributed equally to this work

Correspondence to:

Qing-Xiang Amy Sang, email: [email protected]

Haiyen E. Zhau, email: [email protected]

Keywords: epithelial-to-mesenchymal transition, minichromosome maintenance complex proteins, metastasis, androgen receptor, proteomics

Received: September 06, 2016 Accepted: March 08, 2017 Published: April 05, 2017

ABSTRACT

Metastasis is often associated with epithelial-to-mesenchymal transition (EMT). To understand the molecular mechanisms of this process, we conducted proteomic analysis of androgen-repressed cancer of the prostate (ARCaP), an experimental model of metastatic human prostate cancer. The protein signatures of epithelial (ARCaP_E) and mesenchymal (ARCaP_M) cells were consistent with their phenotypes. Importantly, the expression of mini-chromosome maintenance 3 (MCM3) protein, a crucial subunit of DNA helicase, was significantly higher in ARCaP_M cells than that of ARCaP_E cells. This increased MCM3 protein expression level was verified using Western blot analysis of the ARCaP cell lineages. Furthermore, immunohistochemical analysis of MCM3 protein levels in human prostate tissue specimens showed elevated expression in bone metastasis and advanced human prostate cancer tissue samples. Subcutaneous injection experiments using ARCaP_E and ARCaP_M cells in a mouse model also revealed increased MCM3 protein levels in mesenchymal-derived tumors. This study identifies MCM3 as an upregulated molecule in mesenchymal phenotype of human prostate cancer cells and advanced human prostate cancer specimens, suggesting MCM3 may be a new potential drug target for prostate cancer treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16835

Publication Alerts

Research Papers:

Upregulation of minichromosome maintenance complex component 3 during epithelial-to-mesenchymal transition in human prostate cancer

Abstract